A comparison of cycle control and effect on well-being of monophasic gestodene-, triphasic gestodene- and monophasic desogestrel-containing oral contraceptives

Gynecological Endocrinology

Volumn 14, Issue 2, 2000, Pages 90-98

  Bruni, V ^e   Croxatto, H ^e   De La Cruz, J ^e   Dhont, M ^e   Durlot, F ^a   Fernandes, M T M S ^b   Andrade, R P ^e   Weisberg, E ^c   Rhoa, M ^d  

^a HÔPITAL ANTOINE BÉCLÈRE   (France)

^b Maternidade Daniel de Matos   (Portugal)

^c FAMILY PLANNING NSW   (Australia)

^d WYETH AYERST RESEARCH   (United States)

^e Global Medical Affairs ^*

Author keywords

Cycle control; Desogestrel; Monophasic gestodene; Oral contraceptives; Triphasic gestodene; Well being

Indexed keywords

DESOGESTREL; DESOGESTREL PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS GESTODENE; GESTODENE; ORAL CONTRACEPTIVE AGENT;

ABDOMINAL PAIN; ADULT; ARTICLE; BREAKTHROUGH BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MASTALGIA; MENSTRUAL CYCLE; METRORRHAGIA; MULTICENTER STUDY; NAUSEA; NORMAL HUMAN; ORAL CONTRACEPTION; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SPOTTING; WELLBEING;

EID: 0034029503     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.3109/09513590009167666     Document Type: Article

References (16)

1. 1. Rosenberg MJ, Long SC. Oral contraceptives and cycle control: a critical review of the literature. Adv Contracept 1992;8 (Suppl 1):35-45
2. 2. Rosenberg M, Waugh M. Oral contraceptives and cycle control: are the new progestogens better? Med Dial 1994;415
3. 3. Latin American Oral Contraceptive Study Group. Clinical comparison of monophasic oral contraceptive preparations of gestodene/ethinylestradiol and desogestrel/ethinylestradiol. Contraception 1994;50: 201-14
4. 4. Düsterberg B, Beier S, Schneider WHF, Spona J. Pharmacological features of gestodene in laboratory animals and man. In Breckwoldt M, Düsterberg B, eds. Gestodene, a New Direction in Oral Contraception. Carnforth, UK: Parthenon Publishing, 1988:13-29
5. 5. Brill K, Norpoth T, Schnitker J, Albring M. Clinical experience with a modern low dose oral contraceptive in almost 100 000 users. Contraception 1991;43:101-10
6. 6. Yuzpe AA. Triphasic levonorgestrel: its role in oral contraception. Gynecol Endocrinol 1995;9 (Suppl 2): 29-37
7. 7. Brill K, Müller C, Schnitker J, Albring M. The influence of different low-dose oral contraceptives on intermenstrual bleeding. Adv Contracept 1991;7 (Suppl 2):51-61
8. 8. Moos RH. The development of a menstrual distress questionnaire. Psychosom Med 1968;30:853-67
9. 9. Markum R. Assessment of the reliability of and the effect of neutral instructions on the symptom ratings on the Moos Menstrual Distress Questionnaire. Psychosom Med 1976;38:163-72
10. 10. Gruba GH, Rohrbaugh M. MMPI correlates of menstrual distress. Psychosom Med 1975;37: 265-73
11. 11. Brooks J, Ruble D, Clark A. College women's attitudes and expectations concerning menstrual-related changes. Psychosom Med 1977;39:288-98
12. 12. Paige KE. Effects of oral contraceptives on affective fluctuations associated with the menstrual cycle. Psychosom Med 1971;33:515-37
13. 13. Lacante P. A comparison of cycle control and effect on well-being of monophasic gestodene-, triphasic gestodene-and monophasic desogestrel-containing oral contraceptives. Gynecol Endocrinol 1996;10 (Suppl2):33-41
14. 14. Rabe T, Maletz-Kehry W, Leppien G, et al. Clinical update on triphasic gestodene. Gynecol Endocrinol 1993;7 (Suppl):25-31
15. 15. Andrade RP. Clinical comparison of a triphasic gestodene preparation and a monophasic desogestrel preparation. Gynecol Endocrinol 1993;7 (Suppl):33-41
16. 16. Back DJ, Grimmer SFM, Shenoy N, et al. Plasma concentrations of 3-keto-desogestrel after oral administration of desogestrel and intravenous administration of 3-keto-desogestrel. Contraception 1987;35:619-26